Biofilm formation by Candida spp. isolated from blood culture in patients with or without hematological malignancies

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(2):126-130

​ Malchikova A.O., Klyasova G.A.
10.36488/cmac.2018.2.126-130
candidemia Candida spp biofilm hematological malignancies
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(2):126-130

Objective.

To evaluate the biofilm formation by isolates of Candida spp. obtained from blood culture in patients with or without hematological malignancies.

Materials and Methods.

Biofilm formation by Candida spp. was determined by the method of Pierce C. and Tumbarello M. Isolates with optical density (OD) >0.1 were considered as biofilm-forming.

Results.

A total of 109 isolates of Candida spp. (C. albicans [n=22], C. parapsilosis [n=22], C. tropicalis [n=22], C. krusei [n=21], C. glabrata [n=22]) obtained from patients with or without hematological malignancies (55 and 54 isolates, respectively) were studied. Biofilm formation was determined in 54% of Candida spp. isolates (n=59). Biofilm production was observed more often in non-albicans species compared to C. albicans (60% versus 32%, p=0.02). The incidence of biofilm formation was significantly higher in isolates of C. tropicalis (82%) and C. krusei (81%) compared to isolates of C. parapsilosis (50%), C. albicans (32%), and C. glabrata (27%) (p<0.05). The leading biofilm-forming species were C. tropicalis and C. krusei in the both patient cohorts. Biofilm production was more frequent in C. parapsilosis isolated from patients with hematological malignancies compared to patients without hematological malignancies (73% versus 27%, p=0.03). The lowest incidence of biofilm formation was found in C. albicans (18%) isolated from patients with hematological malignancies and C. glabrata (18%) isolated from patients without hematological malignancies.

Conclusions.

Biofilm formation varied among the Candida spp., with the highest incidence in C. tropicalis (82%) and C. krusei (81%). There were differences in the biofilm formation incidence among Candida spp. isolated from patients with or without hematological malignancies.

Anna O. Malchikova

National Medical Research Center of Hematology, Moscow, Russia

Galina A. Klyasova

National Medical Research Center of Hematology, Moscow, Russia

  • 1. Klyasova G.A., Ohmat V.A., Vasilyeva V.A., et al. Invasive mycoses in patients with acute leukemia and in recipients of hematopoietic stem cells. Results of a multicenter prospective observational study in Russia (RIFI). Gematologija i transfuziologija. 2016;61:19. Russian.
  • 2. Klyasova G.A., Blokhina E.V., Gracheva A.N., et al. Factors influencing recovery in patients with hemoblastoses and candidemia. Terapevticheskij arhiv. 2015;7:77-87. Russian.
  • 3. Veselov A.V., Klimko N.N., Kretchikova O.I., et al. In Vitro Activity of Fluconazole and Voriconazole Against More Than 10000 Yeast Strains: Results of 5-years Prospective ARTEMIS Disk Study in Russia. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2008;10(4):345-354. Russian.
  • 4. Kojic E.M., Darouiche R.O. Candida infections of medical devices. Clin Microbiol Rev. 2004;17:255-267.
  • 5. Tumbarello M., Posteraro B., Trecarichi E.M., et al. Biofilm Production by Candida Species and Inadequate Antifungal Therapy as Predictors of Mortality for Patients with Candidemia. J Clin Microbiol. 2007;45(6):1843-1850.
  • 6. Tumbarello M., Fiori B., Trecarichi E.M., et al. Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. PLoS One. 2012;7:e33705.
  • 7. Tascini C., Sozio E., Corte L., et al. The role of biofilm forming on mortality in patients with candidemia: a study derived from real world data. Infect Dis (Lond). 2018;50(3):214-219.
  • 8. Pierce C.G., Uppuluri P., Tristan A.R., et al. A simple and reproducible 96 well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat ProtoC. 2008;3(9):1494-1500.
  • 9. Melo A.S., Bizerra F.C., Freymuller E., Arthington-Skaggs B.A., Colombo A.L. Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex. Med Mycol. 2011;49:253-262.
  • 10. Nett J., Lincoln L., Marchillo K., et al. Beta-1,3 Glucan as a Test for Central Venous Catheter Biofilm Infection. J Infect Dis. 2007;195(11):1705-1712.
  • 11. Silva S., Rodrigues C. F., Araújo D., et al. Candida Species Biofilms’ Antifungal Resistance. J Fungi (Basel). 2017;3(1). pii:E8.
  • 12. Pannausorn S., Fernandez V., Römling F. Prevalence of biofilm formation in clinical isolates of Candida species causing bloodstream infection. Mycoses. 2012;56:264-272.
  • 13. Gokce G., Cerikcioglu N., Yagci A. Acid proteinase, phospholipase, and biofilm production of Candida species isolated from blood cultures. Mycopathologia. 2007;164:265-269.
  • 14. Kumar C.P.G., Menon T. Biofilm production by clinical isolates of Candida species. Med Mycol. 2006;44:99-101.
  • 15. Pongrácz J., Benedek K., Juhász E., Iván M., Kristóf K. In vitro biofilm production of Candida bloodstream isolates: any association with clinical characteristics? J Med Microbiol. 2016;65:272-277.
  • 16. Shilpa D., Nitika J., Neerja G., Shipra G. Speciation, biofilm formation and antifungal susceptibility of Candida isolates. Int J Res Dev Pharm L Sci. 2017;6(2):2517-2521.
  • 17. Golia S., Hittinahalli V., Sangeetha K.T., Vasudha C.L. Study of biofilm formation as a virulence marker in Candida species isolated from various clinical specimens. J Evol Med Dent Sci. 2012;1(6):1238-1246.
  • 18. Rajendran R., Sherry L., Nile C.J., et al. Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infection – Scotland, 2012-2013. Clin Microbiol Infect. 2016;22: 87-93.
  • 19. Girmenia C., Martino P., De Bernardis F., et al. Rising Incidence of Candida parapsilosis Fungemia in Patients with Hematologic Malignancies: Clinical Aspects, Predisposing Factors, and Differential Pathogenicity of the Causative Strains. Clin Infect Dis. 1996;23:506-514.
  • 20. Agwan V., Butola R., Madan M., et al. Comparison of biofilm formation in clinical isolates of Candida species in a tertiary care center, North India. Indian J Pathol Microbiol. 2015;58:475-478.
  • 21. Tobudic S., Kratzer C., Lassnigg A., et al. Biofilm formation of Candida spp. isolates from patients at a cardiothoracic intensive care unit. Int J Artif Organs. 2011;9:818-823.
  • 22. Prigitano A., Dho G., Lazzarini C., et al. Biofilm production by Candida isolates from a survey of invasive fungal infections in Italian intensive care units. J Chemother. 2012;24(1):61-63.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared